David Sinclair Launches Lifespan, a Scientist-Led Media Platform, as First Human Epigenetic Reprogramming Trial Advances
核心洞察
David Sinclair launches Lifespan Group LLC (搜索) and Lifespan.com, a science media platform built to deliver evidence-based longevity science directly to the public amid growing misinformation.
The launch coincides with National Geographic's cover story on ER-100, Life Biosciences (搜索)' gene therapy using three Yamanaka factors, which received FDA clearance in January 2026 for a human clinical trial targeting ocular aging (搜索).
Lifespan Magazine is written entirely by active longevity scientists, and the platform's podcast already reached #1 in Apple's Health & Fitness category during its first season.
David Sinclair, Professor of Genetics at Harvard Medical School and a prominent figure in longevity research, announced the launch of Lifespan Group LLC (搜索) and its flagship platform, Lifespan.com, on August 7, 2026. The announcement, made on The Joe Rogan Experience, arrives the same week National Geographic published a cover story on the human clinical trial of ER-100 — a gene therapy designed to partially reset the epigenome using three Yamanaka factors (OCT4 (搜索), SOX2 (搜索), and KLF4 (搜索)) delivered via intravitreal injection.
The platform positions itself as a direct response to a wellness media ecosystem that routinely strips context from preliminary findings. "We are entering a period where discoveries in the biology of aging are moving from the laboratory into everyday life, but public understanding has not kept pace," said Dr. Sinclair. "Lifespan was created to bridge that gap by giving people direct access to the science and the scientists shaping the future of health."
The ER-100 Trial and the Regulatory Landscape
The clinical stakes underpinning the launch are genuine. The FDA cleared the ER-100 trial in January 2026, making it among the first human studies of partial epigenetic reprogramming — a mechanism that has demonstrated meaningful results in preclinical vision-loss models. The therapy targets ocular aging (搜索), a strategic choice driven by regulatory reality: the FDA does not recognize aging as a disease, meaning therapies in this space must anchor endpoints to specific age-related conditions rather than a longevity indication. This constraint shapes the broader longevity field trial by trial, and any platform claiming to translate that science for mass audiences carries real editorial responsibility to convey those distinctions accurately.
A Scientist-Written Editorial Model
Lifespan's editorial model is built around content written entirely by active longevity scientists and thought leaders. Kathleen Fitzgerald, Director of Partnerships at Lifespan and former Head of YouTube Programs, emphasized the platform's commitment to nuance: "Scientific discoveries rarely fit into a headline. People deserve to understand what the evidence shows, where it is strongest, and where important questions remain."
The platform launches with Lifespan Magazine, described as a first-of-its-kind longevity publication, alongside the existing Lifespan with Dr. David Sinclair podcast, which reached number one in Apple's Health & Fitness category during its first season. The leadership team includes Emmy Award-winning producer Daniel Salazar III, formerly a producer at NASA, who leads the company's creative vision across film, video, and digital media.
Funding Research Through Community Membership
Lifespan operates on a community-first model, providing members with early access to podcast episodes, full access to Lifespan Magazine and its archives, detailed show notes with references, exclusive conversations with leading longevity researchers, and Ask Me Anything sessions with Dr. Sinclair. The company also supports the Lifespan Foundation, a 501(c)(3) nonprofit organization dedicated to bridging gaps in government research funding, supporting early-career scientists studying aging and longevity, and accelerating therapies that target the root causes of age-related diseases.
The Question of Editorial Independence
A central tension defines the launch: Sinclair holds a scientific and financial stake in Life Biosciences (搜索), the company behind ER-100, and Lifespan.com will inevitably cover epigenetic reprogramming research. How the platform handles disclosure when its founder's own trial data emerges will define whether Lifespan becomes a credible science communication resource or a sophisticated marketing apparatus for a single therapeutic approach. The first ER-100 efficacy readout will serve as the critical test of that editorial independence.